KTN3379: Phase Ib started

Kolltan began an open-label, U.S. Phase Ib trial to evaluate 1,000 mg IV KTN3379 every 2 weeks plus oral Zelboraf twice daily for 4-6 weeks in about 10 patients. Patients whose tumors demonstrate suff...